On February 13, 2015, the U. S. Food and Drug Administration approved lenvatinib (LENVIMA) for the treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer.
On February 13, 2015, the U. S. Food and Drug Administration approved lenvatinib (LENVIMA) for the treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer.